1. Strategies for selecting antibiotics in intensive care units
Hendrik E. Demey, Hilde Jansens, Frank Van Laer, Margareta Ieven, Herman Goossens, Leo L. Bossaert 
Clinical Microbiology and Infection 
Volume 5, Pages S29-S34 (March 1999)
DOI: /j tb00722.x
Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

2. Figure 1
Resistance towards different antibiotics for 1991 and 1995 in a sample of Belgian intensive care units from regional and university hospitals—the NPRS studies [30,31]. SEMC = Inducible Enterobacteriaceae: Serratia, Enterobacter, Morganella and Citrobacter spp.
E. coli + Kleb = non-inducible Enterobacteriaceae
IMI = imipenem; CAZ = ceftazidime; PIP = piperacillin; PTZ = piperacillin + tazobactam; AMK = amikacin; CP = ciprofloxacin.
Permission to cite from the NPRS data was obtained from MSD Belgium. The NPRS data are protected by copyright and can only be used, in part or as a whole, after obtaining written permission from Merck Sharpe & Dohme BV, Waterloosesteenweg 1135, 1180 Brussels, Belgium.
Clinical Microbiology and Infection 1999 5, S29-S34DOI: ( /j tb00722.x)
Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

3. Figure 2
Incidence of E. aerogenes and E. cloacae on the University Hospital Antwerp Department of Intensive Care. An important increase in incidence in the second half of 1996 led to the introduction of cefepime in the blind ‘start’ therapy of nosocomial infections from January 1997 onwards. The dramatic fall in Enterobacter isolation is apparent from the graph.
Clinical Microbiology and Infection 1999 5, S29-S34DOI: ( /j tb00722.x)
Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions